Mantle Cell Lymphoma Market to Register Incremental Growth During the Forecast Period (2022-2032), Asserts DelveInsight | Key Companies – Eli Lilly and Company, Oncternal Therapeutics, Novalgen

DelveInsight’s “Mantle Cell Lymphoma Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Mantle Cell Lymphoma, historical and forecasted epidemiology as well as the Mantle Cell Lymphoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Mantle Cell Lymphoma market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

To Know in detail about the Mantle Cell Lymphoma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Mantle Cell Lymphoma Market Insights

Mantle Cell Lymphoma Overview

Non-Hodgkin’s lymphoma (NHL) is a cancer of the lymphatic system which is a part of the body’s immune system and it occurs when tumors develop from white blood cells (lymphocytes). Many types of cancers can spread to the lymph nodes, but only cancers that start in the lymph tissue are considered lymphomas.

Some of the key facts of the Mantle Cell Lymphoma Market Report: 

• The Mantle Cell Lymphoma market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• Mantle Cell Lymphoma (MCL) is typically an aggressive, rare, form of non-Hodgkin lymphoma (NHL) that arises from cells originating in the “mantle zone”
• In Jan2023, FDA approved Jaypirca to treat relapsed or refractory mantle cell lymphoma in adults who have had at least two lines of systemic therapy, including a BTK inhibitor
• As per Lynch et al., Mantle cell lymphoma (MCL) is a rare subtype of B-cell non-Hodgkin lymphoma (NHL) with an annual incidence of one case per 200 000 people. MCL comprises around 5% of all non-Hodgkins lymphomas.
• Key Mantle Cell Lymphoma Companies: Eli Lilly and Company, Oncternal Therapeutics, Novalgen, Hutchison Medipharma, Eli Lilly and Company, and others
• Key Mantle Cell Lymphoma Therapies: Pirtobrutinib, Zilovertamab, NVG-111, HMPL-760, LOXO-338, and others
• The Mantle Cell Lymphoma epidemiology based on gender analyzed that Mantle Cell Lymphoma frequency is usually more in males than in females

Get a Free sample for the Mantle Cell Lymphoma Market Report –

https://www.delveinsight.com/sample-request/mantle-cell-lymphoma-market

Key benefits of the Mantle Cell Lymphoma Market report:

1. Mantle Cell Lymphoma market report covers a descriptive overview and comprehensive insight of the Mantle Cell Lymphoma Epidemiology and Mantle Cell Lymphoma market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. The Mantle Cell Lymphoma market report provides insights on the current and emerging therapies.
3. Mantle Cell Lymphoma market report provides a global historical and forecasted market covering drug outreach in 7MM.
4. The Mantle Cell Lymphoma market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Mantle Cell Lymphoma market.

Download the report to understand which factors are driving Mantle Cell Lymphoma epidemiology trends @ Mantle Cell Lymphoma Epidemiological Insights 

Mantle Cell Lymphoma Market  

The dynamics of the Mantle Cell Lymphoma market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032.  

Mantle Cell Lymphoma Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Mantle Cell Lymphoma Epidemiology Segmentation:

The Mantle Cell Lymphoma market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Mantle Cell Lymphoma
• Prevalent Cases of Mantle Cell Lymphoma by severity
• Gender-specific Prevalence of Mantle Cell Lymphoma
• Diagnosed Cases of Episodic and Chronic Mantle Cell Lymphoma

Mantle Cell Lymphoma Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Mantle Cell Lymphoma market or expected to get launched during the study period. The analysis covers Mantle Cell Lymphoma market uptake by drugs, patient uptake by therapies, and sales of each drug.  

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Mantle Cell Lymphoma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Discover more about therapies set to grab major Mantle Cell Lymphoma market share @ Mantle Cell Lymphoma market forecast 

Mantle Cell Lymphoma Therapies and Key Companies

• Pirtobrutinib: Eli Lilly and Company
• Zilovertamab: Oncternal Therapeutics
• NVG-111: Novalgen
• HMPL-760: Hutchison Medipharma
• LOXO-338: Eli Lilly and Company

Mantle Cell Lymphoma Market Drivers

• Premium-price agents with superior efficacy such as CAR-T cell therapies and kinase inhibitors are expected to dominate the Mantle cell lymphoma market

Scope of the Mantle Cell Lymphoma Market Report

• Study Period: 2019–2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Mantle Cell Lymphoma Companies: Eli Lilly and Company, Oncternal Therapeutics, Novalgen, Hutchison Medipharma, Eli Lilly and Company, and others
• Key Mantle Cell Lymphoma Therapies: Pirtobrutinib, Zilovertamab, NVG-111, HMPL-760, LOXO-338, and others
• Mantle Cell Lymphoma Therapeutic Assessment: Mantle Cell Lymphoma current marketed and Mantle Cell Lymphoma emerging therapies
• Mantle Cell Lymphoma Market Dynamics: Mantle Cell Lymphoma market drivers and Mantle Cell Lymphoma market barriers 
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Mantle Cell Lymphoma Unmet Needs, KOL’s views, Analyst’s views, Mantle Cell Lymphoma Market Access and Reimbursement 

Mantle Cell Lymphoma Market Barriers

• Currently limited treatment options available for relapsed and refractory cases in MCL
• Increasing incident case of Mantle Cell Lymphoma, mainly in geriatric population

Table of Contents 

1. Mantle Cell Lymphoma Market Report Introduction

2. Executive Summary for Mantle Cell Lymphoma

3. SWOT analysis of Mantle Cell Lymphoma

4. Mantle Cell Lymphoma Patient Share (%) Overview at a Glance

5. Mantle Cell Lymphoma Market Overview at a Glance

6. Mantle Cell Lymphoma Disease Background and Overview

7. Mantle Cell Lymphoma Epidemiology and Patient Population

8. Country-Specific Patient Population of Mantle Cell Lymphoma 

9. Mantle Cell Lymphoma Current Treatment and Medical Practices

10. Mantle Cell Lymphoma Unmet Needs

11. Mantle Cell Lymphoma Emerging Therapies

12. Mantle Cell Lymphoma Market Outlook

13. Country-Wise Mantle Cell Lymphoma Market Analysis (2019–2032)

14. Mantle Cell Lymphoma Market Access and Reimbursement of Therapies

15. Mantle Cell Lymphoma Market Drivers

16. Mantle Cell Lymphoma Market Barriers

17.  Mantle Cell Lymphoma Appendix

18. Mantle Cell Lymphoma Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

To know more about Mantle Cell Lymphoma treatment, visit @ Mantle Cell Lymphoma Medications

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services